Medicines in development in 2009 for breast cancer

[SciMedWeb]

Medicines in development in 2009 for breast cancer:

● ABI-008 Phase I/II
● ABT-751 Phase II
● ABT-869 Phase II
● aderbasib (INCB7839) Phase II
● Advexin (contusugene ladenovec) Phase II
● AE-37 Phase II
● AG-14699 Phase II
● Alimta (pemetrexed) Phase II
● AMG 386 Phase II
● AMG 479 Phase II
● Amplimexon (imexon) Phase I
● anti-CD3 (activated T-cells) Phase I
● anti-MUC1 mAb Phase I
● anti-PEM mAb Phase I/II
● Armala (pazopanib) Phase III
● Aromasin (exemestane) Phase III
● ARRY-543 Phase I/II
● arzoxifene Phase III
● AS-1402 Phase II
● AVE1642 (anti-IGF-1R mAb) Phase II
● AZD2281 Phase II
● AZD4992 Phase I
● BIBW 2992 Phase II
● bleomycin Phase I
● bosutinib Phase II
● BSI-201 Phase II
● BTSCAN Phase I
● BZL-101 Bionovo Phase II
● Capoxigem (apricoxib) Phase II
● CDX-1307 Phase I
● cediranib Phase II
● CNF-2024 Phase I
● CP-751871 Phase II
● CR011-vcMMAE Phase II
● deforolimus (MK-8669) Phase II
● Doxil (doxorubicin liposome injection)
● doxorubicin (liposomal) Phase III
● enzastaurin (LY317615) Phase II
● eribulin mesylate (E7389) Phase III
● Genasense (oblimersen) Phase II
● glufosfamide Phase II
● GRN-163L Phase I/II
● HER2-antigen- specific cancer immunotherapeutic Phase II
● HER2/neu peptide vaccine Phase I/II
● Hycamtin (topotecan) Phase II
● IMC-1121B Phase III
● IMC-A12 Phase II
● IMT-1012 Phase I
● INGN 225 (p53 vaccine) Phase I/II
● ispinesib Phase II
● Ixempra (ixabepilone)
● lapuleucel-T Phase I
● LEP-ETU Phase II
● LOR-2040 Phase II
● Lymphoseek Phase III
● milataxel Phase II
● MK-0646 Phase I
● MK-0752 Phase I
● MKC 1 Phase II
● motesanib Phase II
● NBI-42902 Phase I
● neratinib (HKI272) Phase III
● NeuVax (E75 cancer vaccine) Phase II
● Nexavar (sorafenib) Phase II
● NOV-002 Phase II
● OBP-301 Phase I
● OGX-427 Phase I
● OPT-22 Phase I
● panobinostat Phase I/II
● patupilone (EPO906) Phase II
● PD-332991 Phase I/II
● pertuzumab Phase III
● PTC-299 Phase I/II
● PX-1032 (HER2 breast cancer vaccine) Phase I/II
● Quinamed (amonafide) Phase II
● R1507 Phase II
● retaspimycin (IPI 504) Phase II
● Reximmune-C Phase I/II
● Rexin-G (tumor-targeted gene therapy) Phase I/II
● sagopilone Phase II
● Sarasar (lonafarnib) Phase II
● satraplatin Phase II
● SCH-727965 Phase II
● SF1 Phase I/II
● SNDX-275 Phase II
● SU-14813 Phase II
● Sutent (sunitinib) Phase III
● TamoGel (afimoxifene) Phase II
● Tarceva (erlotinib) Phase II
● TAS-108 Phase II
● Telcyta (canfosfamide) Phase II
● tesmilifene Phase III
● TheraCIM (nimotuzumab) Phase I
● Thermodox Phase I/II
● trastuzumab-DM1 Phase III
● Trelstar (triptorelin) Phase III
● tremelimumab Phase I
● trilostane
● vinflunine Phase III
● WX-671 Phase II
● Yondelis (trabectedin) Phase II
● Zactima (vandetanib) Phase II
● Zolinza (vorinostat) Phase II
● ZYC300 Phase I

InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)